ASCELIA PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.23 SEK | -1.81% |
|
-8.43% | +173.89% |
| 21/05 | Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024 | |
| 16/05 | Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 16, 2024 |
Presenter SpeechClaus Thestrup (Attendees)Good afternoon, and welcome to today's event. With m...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
Calendar
15/08/2024
- Q2 2024 Earnings Release
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +173.89% | 2.96Cr | |
| +40.80% | 5.37TCr | |
| +35.79% | 3.89TCr | |
| -8.05% | 3.88TCr | |
| -8.98% | 2.73TCr | |
| +10.69% | 2.59TCr | |
| -16.21% | 2.03TCr | |
| +31.00% | 1.28TCr | |
| +28.51% | 1.22TCr | |
| -1.67% | 1.2TCr |
- Stock Market
- Equities
- ACE Stock
- News Ascelia Pharma AB
- Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024
